These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12559790)

  • 1. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.
    Smahel M; Síma P; Ludvíková V; Marinov I; Pokorná D; Vonka V
    Vaccine; 2003 Mar; 21(11-12):1125-36. PubMed ID: 12559790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.
    Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M
    J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccines against HPV-16 E7-expressing tumour cells.
    De Marco F; Hallez S; Brulet JM; Gesché F; Marzano P; Flamini S; Marcante ML; Venuti A
    Anticancer Res; 2003; 23(2B):1449-54. PubMed ID: 12820408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase.
    Smahel M; Pokorná D; Macková J; Vlasák J
    J Gene Med; 2004 Oct; 6(10):1092-101. PubMed ID: 15386741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells.
    Smahel M; Síma P; Ludvíková V; Vonka V
    Virology; 2001 Mar; 281(2):231-8. PubMed ID: 11277695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes and the activated ras oncogene.
    Smahel M; Sobotkova E; Vonka V; Hamsikova E; Zak R; Kitasato H; Ludvikova V
    Oncol Rep; 1999; 6(1):211-5. PubMed ID: 9864430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16.
    Smahel M; Sobotková E; Bubeník J; Símová J; Zák R; Ludviková V; Hájková R; Kovarík J; Jelínek F; Povýsil C; Marinov J; Vonka V
    Br J Cancer; 2001 Feb; 84(3):374-80. PubMed ID: 11225590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
    Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
    Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cell lines derived from tumors induced by TC-1 cells in mice preimmunized against HPV16 E7 oncoprotein.
    Smahel M; Smahelová J; Tejklová P; Tachezy R; Marinov I
    Int J Oncol; 2005 Sep; 27(3):731-42. PubMed ID: 16077923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules.
    Li H; Ou X; Xiong J
    Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
    Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation.
    Kotecha MT; Afghan RK; Vasilikopoulou E; Wilson E; Marsh P; Kast WM; Davies DH; Caparros-Wanderley W
    Vaccine; 2003 Jun; 21(19-20):2506-15. PubMed ID: 12744885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
    Tseng CW; Trimble C; Zeng Q; Monie A; Alvarez RD; Huh WK; Hoory T; Wang MC; Hung CF; Wu TC
    Cancer Immunol Immunother; 2009 May; 58(5):737-48. PubMed ID: 18815785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model.
    Li J; Sun Y; Garen A
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16232-6. PubMed ID: 12446839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical immunogenicity and anti-tumour efficacy of a deleted recombinant human papillomavirus type 16 E7 protein.
    Hallez S; Brulet JM; Vandooren C; Maudoux F; Thomas S; Heinderickx M; Bollen A; Wattiez R; Jacquet A
    Anticancer Res; 2004; 24(4):2265-75. PubMed ID: 15330171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.
    Liu W; Gao F; Zhao KN; Zhao W; Fernando GJ; Thomas R; Frazer IH
    Virology; 2002 Sep; 301(1):43-52. PubMed ID: 12359445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function.
    Peng X; Hussain SF; Paterson Y
    J Immunol; 2004 May; 172(10):6030-8. PubMed ID: 15128786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.